➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,010,530

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,010,530 protect, and when does it expire?

Patent 10,010,530 protects NUBEQA and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 10,010,530
Title:Carboxamide derivative and its diastereomers in stable crystalline form
Abstract: The present disclosure relates to solid crystalline forms of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-- hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament. ##STR00001##
Inventor(s): Tormakangas; Olli (Turku, FI), Heikkinen; Terhi (Lieto, FI)
Assignee: Orlon Corporation (Espoo, FI)
Application Number:15/547,193
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 10,010,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Healthcare NUBEQA darolutamide TABLET;ORAL 212099-001 Jul 30, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,010,530

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Finland20150033Jan 30, 2015
PCT Information
PCT FiledJanuary 28, 2016PCT Application Number:PCT/FI2016/050054
PCT Publication Date:August 04, 2016PCT Publication Number: WO2016/120530

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.